Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Investor Day (September 2009)
25 slides from Coloplast A/s Class B's investor day presentation, Sep 29, 2009
Slide 1: Chronic Care
Coloplast Capital Market Day 2009 Chronic Care Coloplast p Capital p Market Day y 2009 Jan Rolin Frederiksen, President Coloplast US 29 September 2009 Chronic Care Page 1
Slide 2: Agenda
Coloplast Capital Market Day 2009 Agenda • Chronic Care Product Portfolio • Ostomy Care • Continence Care • Wound and Skin Care 29 September 2009 Chronic Care Page 2
Slide 3: Chronic Care Portfolio covers four product-business areas addressing chronic conditions
Coloplast Capital Market Day 2009 Chronic Care Portfolio covers four product-business p areas addressing chronic conditions 29 September 2009 Chronic Care Page 3
Slide 4: Agenda
Coloplast Capital Market Day 2009 Agenda • Chronic Care Product Portfolio • Ostomy Care • Continence Care • Wound and Skin Care 29 September 2009 Chronic Care Page 4
Slide 5: The US ostomy market is well defined and familiar to Coloplast
Coloplast Capital Market Day 2009 The US ostomy y market is well defined and familiar to Coloplast Underlying y g conditions Customer Groups Call points • Colorectal cancer (33%) Primary • Hospital nurses • Inflammatory bowel disease (35%) • Nurses, mainly Wound, Ostomy • Hospital materials manageme
Slide 6: The market for ostomy products is expected to grow slowly
Coloplast Capital Market Day 2009 The market for ostomyy p products is expected p to g grow slowlyy with both positive and negative factors impacting growth US Market estimate development in value 2-4% RoW Europe Americas 2007 2008 2009 2010 2011 2012 2013 US S Market Drivers US S Market Limiters US
Slide 7: Hollister and ConvaTec dominate the market, and three local competitors have only 5%
Coloplast Capital Market Day 2009 Hollister and ConvaTec dominate the market,, and three local competitors have only 5% market share Market Size ($M) 350 Competition 300 250 200 150 100 50 0 US Market (2009) 29 September 2009 Chronic Care Page 7
Slide 8: There are four primary customer segments and call points
Coloplast Capital Market Day 2009 There are four p primary y customer segments g and call p points,, where ostomy patients are cared for Account type Description Rationale 1. Hospitals Acute care hospitals, independent or part of Hospital generate New Patient Discharges and an Integrated Delivery Ne
Slide 9: Summary
Coloplast Capital Market Day 2009 Summary • Large well defined attractive market • Coloplast well positioned with superior products d t and d programs • Focused national sales coverage with emphasis on • new patient discharge • patient retention • competitor conversion 29 September 2009 Chronic Care
Slide 10: Agenda
Coloplast Capital Market Day 2009 Agenda • Chronic Care Product Portfolio • Ostomy Care • Continence Care • Wound and Skin Care 29 September 2009 Chronic Care Page 10
Slide 11: Introducing Continence Care in the US
Coloplast Capital Market Day 2009 Introducing Continence Care in the US Underlying Conditions Customer Groups Call points • Spinal Cord Injury, SCI Primaryy • Rehabilitation centers • Spina Bifida, SB • Clinicians • Urology clinics • Multiple Sclerosis, MS • End-users • Pediatric clinics • BPH patie
Slide 12: Growth of urinary continence supplies market accelerated by 2008 Medicare reimbursement change
Coloplast Capital Market Day 2009 Growth of urinaryy continence supplies pp market has been accelerated by 2008 Medicare reimbursement change US Market estimate development p in value 6-8% RoW Europe Americas 2007 2008 2009 2010 2011 2012 US Market Drivers US Market Limiters US Market Trends Reimbur
Slide 13: The urinary continence market consists of four product categories and has numerous competitors
Coloplast Capital Market Day 2009 The urinaryy continence market consists of four product p categories and has numerous competitors Market Size ($M) Competition p 400 350 Male External Catheters 300 Urine Collection Bags 250 I Intermittent i Catheters C h 200 150 100 Foley Catheters 50 0 US Market (
Slide 14: Coloplast has market leading positions in intermittent and male external catheters
Coloplast Capital Market Day 2009 Coloplast has market leading positions in intermittent and male external catheters. Bard is overall market leader. 2008, millions USD Coloplast 180 90 60 55 385 B d Bard Covidien Medline Hollister Other Foley Intermittent Urine Male External Total Catheters Catheter
Slide 15: Medicare reimbursement policy will expand intermittent catheter market by 70-80%
Coloplast Capital Market Day 2009 Medicare reimbursement policy will expand intermittent catheter market by 70-80% Market Penetration single g use Revenue in $ Total IC market % penetration 160 150 140 Key y Conclusions 130 90 75% 80% • 16 months after the policy 120 110 70% change about 50% of tota
Slide 16: Four clinical and two distribution primary call points in the urinary continence market
Coloplast Capital Market Day 2009 Four clinical and two distribution p primary y call p points in the urinary continence market Account type Description Rationale 1. Spinal Cord Injury Specialized model SCI centers. centers 2. Spina Bifida centers Including Shriners hospitals and pediatric centers S
Slide 17: Summary
Coloplast Capital Market Day 2009 Summary • Market trends very favorable enabled by reimbursement policy change • Strong St leading l di supplier li off IIntermittent t itt t and d male external catheters • Focus on expanding IC market through education of • Clinical decision makers • Dealers • End
Slide 18: Agenda
Coloplast Capital Market Day 2009 Agenda • Chronic Care Product Portfolio • Ostomy Care • Continence Care • Wound and Skin Care 29 September 2009 Chronic Care Page 18
Slide 19: Introducing Wound and Skin Care in the US
Coloplast Capital Market Day 2009 Introducing Wound and Skin Care in the US Underlying conditions Customer Groups Call points Chronic Wounds Hospitals / IDNs • Wound/Ostomy/Continence • Leg ulcers • Clinical committees Nurses • Diabetic foot ulcers • New product committees • Intensive Care Units • P
Slide 20: Recent changes in reimbursement policies drive healthy growth for wound and skin products
Coloplast Capital Market Day 2009 Recent changes in reimbursement policies drive healthy growth for wound and skin products US Market estimate development p in value 6-8% RoW Europe Americas 2007 2008 2009 2010 2011 2012 US Market Drivers US Market Limiters US Market Trends Hospital acquired conditi
Slide 21: The US market for wound and skin care is fragmented with ConvaTec as overall leader
Coloplast Capital Market Day 2009 The US market for wound and skin care is fragmented with many players and ConvaTec as overall leader Market Size ($M) C Competition titi 1200 1000 Wound Care 800 600 400 Skin Care 200 0 US WSC Market (2009) Source GHX Data: FY02 2009 29 September 2009 Chronic Care P
Slide 22: Over 50% of wound and skin market is in the acute care segment
Coloplast Capital Market Day 2009 Over 50% of wound and skin market is in the acute care segment and the value per account is higher Account type Description Rationale Groups of hospitals / large More than 50% of skin care market is in acute 1. IDNs / Hospitals hospitals hospitals. Prevention of ski
Slide 23: Summary
Coloplast Capital Market Day 2009 Summary • Strong Wound care portfolio in a fragmented and competitive market place with high potential • Skin care portfolio provides unique opportunity to exploit Hospital Acquired Conditions policy change 29 September 2009 Chronic Care Page 23
Slide 24: Chronic Care Portfolio – Overall Summary
Coloplast Capital Market Day 2009 Chronic Care Portfolio – Overall Summary 29 September 2009 Chronic Care Page 24
Slide 25: Coloplast Capital Market Day 2009
Coloplast Capital Market Day 2009 ? ? ?? ? ? ? ? ? ? ? ? ? ?? ? ? 29 September 2009 Chronic Care Page 25